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ABSTRACT
Introduction: The effectiveness of inhaled
therapies can be influenced by many factors,
including the type of inhaler, which may have
clinical implications. We report a real-world,
multicenter, open-label, non-randomized, non-
interventional study conducted by 200 pulmo-
nologists across 200 centers in Hungary. The
effectiveness of budesonide/formoterol inhala-
tion therapy in daily clinical practice, delivered
via the Bufomix Easyhaler, was evaluated in
patients with asthma, chronic obstructive pul-
monary disease (COPD) and asthma-COPD
overlap (ACO).
Methods: Effectiveness was assessed after
12 weeks of treatment by spirometry, the
Asthma Control Test, mini-Asthma Quality of
Life Questionnaire, COPD Assessment Test and
modified Medical Research Council dyspnea
scale. Patient satisfaction with the Bufomix
Easyhaler and physicians’ assessments (ease of
use and time taken to learn the technique) were
also assessed.
Results: A total of 1498 patients with obstruc-
tive airway disease were evaluated (asthma:
n = 621; COPD: n = 778; ACO: n = 99), of
whom 455 (30.4%) were newly diagnosed
inhaler-naı¨ve patients and 1043 (69.6%) were
switching from other inhalers. Significant
improvements in lung function, disease control
and health-related quality of life measures (all
p B 0.002) were reported after 12 weeks of
Bufomix Easyhaler use. Improvements were
observed in both inhaler-naı¨ve patients and
those who switched to a Bufomix Easyhaler
from other devices. After switching, 72.4% of
patients regarded the Bufomix Easyhaler as
‘very good’ and[ 90.0% of physicians descri-
bed the Bufomix Easyhaler as easy to teach;
73.8% and 98.9% of patients learned the tech-
nique within 5 and 10 min of teaching,
respectively.
Conclusion: Twelve weeks’ treatment with the
Bufomix Easyhaler resulted in significant
improvements in disease control and quality of
life. The Bufomix Easyhaler was considered
easy to use, and most patients were satisfied
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with the inhaler. Results confirm the real-world
effectiveness of the Bufomix Easyhaler in the
treatment of adult outpatients with obstructive
airway disease.
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INTRODUCTION
Asthma and chronic obstructive pulmonary
disease (COPD) are highly prevalent chronic
respiratory diseases and leading causes of mor-
bidity and mortality worldwide [1]. Asthma-
COPD overlap (ACO) is a challenging pheno-
type of obstructive airway disease where
patients have clinical features of both asthma
and COPD [2, 3]. Despite the presence of
established treatment guidelines for asthma [2],
many asthma patients still experience persistent
symptoms and therefore poor disease control
[4, 5]. Recent data indicate that improvement of
asthma control continues to be a public health
concern in the USA and Europe, as asthma is
not well controlled or managed on national
levels [6, 7]. Furthermore, most patients with
COPD are symptomatic [8], despite the available
therapies, such as bronchodilators and inhaled
corticosteroids (ICS).
Inhaled therapy is recommended as the pri-
mary route of administration for medication
used to manage asthma [9] and COPD [10]. An
additive effect in alleviating asthma symptoms
has been demonstrated with combination
therapy of budesonide (an ICS) and formoterol
fumarate [a long-acting b2-adrenergic agonist
(LABA)] (budesonide/formoterol) [11]. Budes-
onide/formoterol is also a recommended treat-
ment alternative for patients with COPD who
have a history of exacerbations [12]. In patients
with ACO, treatment with low-to-moderate-
dose ICS is recommended with the addition of a
LABA and/or long-acting muscarinic receptor
antagonists where necessary [2].
Many types of devices for delivery of inhaled
drugs are available [13]. Effectiveness of the
inhaler is crucial since a suboptimal inhalation
technique may have clinical implications [14];
effectiveness can be influenced by several fac-
tors, including age, gender, education, inhala-
tion technique and type of inhaler used [15, 16].
The Bufomix Easyhaler (Orion Pharma,
Espoo, Finland) is a multidose dry powder
inhaler for the administration of budes-
onide/formoterol in combination, indicated for
the treatment of adult patients with COPD and
asthma, and adolescents (aged 12–17 years)
with asthma [17], approved in several European
countries. The Bufomix Easyhaler has demon-
strated similar in vitro flow rate dependency
compared with the Turbuhaler, using clini-
cally relevant air flow rates collected from
patients with asthma and COPD [18]. Addi-
tionally, superior dose consistency was observed
compared with the Turbuhaler at different
clinically relevant in vitro flow rates [19].
Therapeutic equivalence and equivalent bron-
chodilator efficacy have also been reported
between the two inhalers [20, 21].
Recent real-world evidence, collected in
patients with asthma, has demonstrated the
clinical effectiveness of the Bufomix Easyhaler
[22]; however, patient satisfaction with the
Bufomix Easyhaler is yet to be evaluated fur-
ther. The aim of this non-randomized, open-
label, real-world study was to evaluate the
effectiveness of Bufomix Easyhaler therapy for
asthma, COPD and ACO in everyday clinical
practice in Hungary.
METHODS
Study Design
This real-world, multicenter, open-label, non-
randomized, non-interventional study was
conducted by 200 pulmonologists across 200
Hungarian centers and was a nationwide
assessment of inhaler effectiveness in patients
diagnosed with asthma, COPD and ACO who
started using the Bufomix Easyhaler, including
those who switched from their current inhaler.
The trial was registered with the National
Pharmaceutical Institute of Hungary (registra-
tion no. OGYE´I/13,942-5/2016). Test devices
were distributed from Orion Pharma to
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participating centers prior to the start of the
study, which was conducted between 1 May
2016 and 31 December 2017. Patients made
three visits to their pulmonologist; all mea-
surements were evaluated as change from
baseline (visit 1, when patients switched from
their current inhaler to Bufomix Easyhaler) to
visit 3 (after 12 weeks’ treatment with Bufomix
Easyhaler). The dose and dosing regimen were
agreed between the patient and their pulmo-
nologist at the first visit. The following doses
(lg/inhalation of budesonide/formoterol) were
used, according to the Bufomix Easyhaler sum-
mary of product characteristics (SPC) [23, 24]:
160/4.5 in patients with asthma receiving 2 9 1
inhalations per day or patients with COPD
receiving 2 9 2 inhalations per day; 320/9 in
patients with asthma receiving 2 9 1 or 2 9 2
inhalations per day or patients with COPD
receiving 2 9 2 inhalations per day. Patients
with ACO were treated in accordance with
Global Initiative for Asthma (GINA) guidelines
[2]. The daily dose, per patient, was the same
across the whole study period.
Demographic data, spirometry, current
medication and smoking history were recorded
using asthma and COPD assessment forms,
completed during each visit by recruiting
physicians (see supplementary material).
Patients
Patients were identified based on their atten-
dance at routine clinical appointments at
widespread centers in Hungary that met Good
Clinical Practice requirements. Eligible patients
were adults ([ 18 years old) with a physician-led
diagnosis of asthma or COPD (according to
GINA or Global Initiative for Chronic Obstruc-
tive Lung Disease therapeutic guidelines [2, 10])
or ACO (also according to GINA guidelines) and
without an exacerbation in the 4 weeks prior to
enrollment. Additionally, patients whose dis-
ease could not be controlled with pre-existing
therapy, whose proficiency in the usage of the
previously prescribed inhaler was unsatisfac-
tory, or who did not feel comfortable with their
device, were also eligible for this study. Patients
were excluded from the study if they had a
hypersensitivity to budesonide, formoterol or
lactose or if they were pregnant or breastfeeding
[16]. The study was approved by the National
Scientific and Research Ethics Committee of
Hungary.
All procedures were performed in accordance
with the ethical standards of the National Sci-
entific and Research Ethics Committee of Hun-
gary (the study was approved by this body) and
with the 1964 Helsinki declaration and its later
amendments or comparable ethical standards.
Written informed consent was obtained from
all individual participants included in the study
prior to study commencement.
End Points and Assessments
Primary outcomes were change in patient-re-
ported outcome (PRO) measures after 12 weeks
of treatment; PRO measures were assessed using
the following co-primary end points: the
Asthma Control Test (ACT) [25], mini-Asthma
Quality of Life Questionnaire (mini AQLQ) [26],
COPD Assessment Test (CAT) [27] and modified
Medical Research Council dyspnea scale
(mMRC) [28]. All other outcomes were assessed
as secondary end points.
Disease control was assessed during each
visit using either the ACT (ACT score B 19
indicates poorly or not well controlled asthma)
or the CAT (CAT score of[20 indicates a high
impact of COPD on their daily life); health-re-
lated quality of life (HRQoL) measures were
assessed using the mini-AQLQ (mini-AQLQ
score\4 indicates very limited daily life due to
asthma) and the mMRC (mMRC score[1
indicates difficulty in walking due to
breathlessness).
To evaluate the usage of a previous inhaler (if
it existed) and the Bufomix Easyhaler in
everyday life, patients received a previously
validated questionnaire (e.g., how easy was it to
learn, use, clean and inhale from the inhaler,
how much the inhaler use helped in everyday
activities such as sports, walking, etc., and
patients’ perception/preference for their inha-
ler) [29]. This self-assessment was completed
during all visits (Table 1). Additionally, patient
satisfaction using a previous inhaler (if it
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existed) or the Bufomix Easyhaler was ana-
lyzed at visit one using closed questions scored
on a six-point scale: one (very good) to six
(unsatisfactory). Before the start of the study,
participating pulmonologists were trained in
how to use the Bufomix Easyhaler by Orion
Pharma staff; physicians then showed individ-
ual patients how to handle the device at the first
visit, according to the SPC [23, 24]. After train-
ing the patient in using the Bufomix
Easyhaler, physicians were asked to assess the
ease of use (through visits 1–3) and the time
taken to teach the patient how to use the device
(at visit 1) (Table S1). For patients whose disease
could not be controlled with pre-existing ther-
apy, or whose proficiency in the usage of their
previous inhaler was unsatisfactory, pulmo-
nologists assessed the use of the previous device
by asking the same questions provided for the
Bufomix Easyhaler.
Forced expiratory volume in 1 s (FEV1) was
determined using spirometry through visits 1–3
(measured as a pre-bronchodilator assessment),
according to the American Thoracic Society/
European Respiratory Society task force guide-
lines [30, 31] and expressed as FEV1% predicted
normal.
Statistical Analyses
All data were expressed as percentages or means
with standard deviations. The Wilcoxon’s
signed rank test was used to compare change
from baseline; p\ 0.05 was considered statisti-
cally significant. No power calculations were
performed because of the real-world nature of
the study.
All questionnaires were provided in e-format
case report forms (CRFs) by VIT Ltd., Hungary;
scores were input into these CRFs by the pul-
monologist at each visit after they read each
question to the patient.
All statistical analyses were performed using
SAS software, version 9.4 for Windows (SAS
Institute Inc., Cary, NC, USA).
RESULTS
Baseline Patient Characteristics
Overall, 1498 patients with obstructive airway
disease were evaluated (asthma: n = 621; COPD:
n = 778; ACO: n = 99). Baseline characteristics
are summarized in Table 2. Patients with
asthma were younger, with a mean age of
53.2 years [standard deviation (SD), 16.3], than
those with COPD (mean age 64.1 years; SD, 9.9)
and ACO (mean age 61.9 years; SD 10.6).
Table 1 Patient assessment of the inhaler and complexity
of the instructions for use
Question Please select most
appropriate
Patient perspective on Easyhaler use
How easy was it to learn how to use
the inhaler?
1 (very easy)–6
(difﬁcult)
How easy was it to prepare the
inhaler?
1 (very easy)–6
(difﬁcult)
How easy was it to use the inhaler? 1 (very easy)–6
(difﬁcult)
How easy was it to successfully
inhale from the inhaler?
1 (very easy)–6
(difﬁcult)
How easy was it to keep the inhaler
clean and ready-to-use?
1 (very easy)–6
(difﬁcult)
How easy are daily activities (e.g.,
sports, walking) with the inhaler?
1 (very easy)–6
(difﬁcult)
How easy was it to handle the
inhaler (according to the size and
weight of the inhaler)?
1 (very easy)–6
(difﬁcult)
Do you feel any discomfort related to the following when
using the inhaler?
Smell Yes/no
Taste
Coughing
Huskiness
Other
How would you evaluate the inhaler
in general?
1 (very good)–6
(not good)
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Overall, patients had a mean FEV1 % predicted
of 62.2% (21.8). The majority of patients were
female (60.4%), had a smoking history (59.0%)
and were educated up to high school (88.9%).
At baseline (visit 1), 455 (30.4%) patients
were new to inhaler use, and 1043 (69.6%)
patients switched to the Bufomix Easyhaler
from other inhalers. The three most commonly
used inhalers were the Metered Dose Inhaler
(MDI), Turbuhaler and Diskus (Fig. S1). At
baseline, most of the 1498 participants had
poorly controlled asthma or experienced a high
impact of COPD on their daily life. Accordingly,
398 (64.1%) patients with asthma, 563 (72.4%)
patients with COPD and 82 (82.8%) patients
with ACO were using a maintenance medica-
tion at baseline.
Effect of Bufomix Easyhaler on Disease
Control
After switching to the Easyhaler from other
devices, significant improvement occurred in all
groups of patients with asthma and COPD,
including inhaler-naı¨ve patients (Tables 3, 4).
Patients with asthma had a mean (SD) ACT
score of 14.2 (4.1) at baseline; disease control
was significantly improved by visit 3
(p\ 0.001), when the mean (SD) ACT score was
21.0 (2.7). By visit 3, 73.2% of all patients with
asthma (asthma and ACO) had ‘well-controlled’
disease (Fig. 1a). Furthermore, a marked reduc-
tion in reliever inhaler use was observed at visit
3; 87.2% of all patients with asthma reportedly
used their reliever inhaler no more than once a
week compared with 32.2% of patients at visit 1
(Fig. 2).
Patients with COPD had a mean (SD) CAT
score of 24.2 (5.7) at baseline. Disease control
was significantly improved by visit 3 (p\ 0.001)
when the mean (SD) CAT score was 18.2 (5.1).
By visit 3, 67.7% of all COPD patients (COPD
and ACO) experienced low-medium disease
impact on their QoL (CAT B 20; Fig. 1b).
Overall, twelve weeks of treatment with the
Bufomix Easyhaler resulted in a significant
improvement in lung function (FEV1% pre-
dicted). In total, mean (SD) FEV1% predicted
increased from 62.2% (21.8) at baseline to
69.9% (23.1) at visit 3 (p\0.001). Similar
improvements in lung function were observed
in all patient groups; patients with asthma,
COPD and ACO (Tables 3, 4). Most importantly,
significant improvement in lung function was
Table 2 Baseline demographics and patient characteristics
(N = 1498)
Asthma
(n = 621)
ACO
(n = 99)
COPD
(n = 778)
Age (years),
mean (SD)
53.2 (16.3) 61.9 (10.6) 64.1 (9.9)
Gender
(female),
n (%)a
430 (69.4) 60 (61.2) 413 (53.2)
Height (cm),
mean
165.5 167.1 165.0
Weight (kg),
mean
78.1 77.3 75.7
FEV1%
predicted
76.7 (19.3) 56.7 (18.3) 51.3 (17.0)
Education, n (%)a
Primary school 156 (25.2) 43 (43.9) 381 (49.1)
High school 359 (58.1) 49 (50.0) 343 (44.2)
University or
college degree
103 (16.7) 6 (6.1) 52 (6.7)
Disease control, mean (SD)
ACT 14.2 (4.1) 13.6 (4.1) n/a
CAT n/a 23.7 (6.5) 24.2 (5.7)
HRQoL
Mini-AQLQ 3.8 (0.9) 3.7 (0.9) n/a
mMRC
dyspnea scale
n/a 1.8 (0.9) 1.9 (0.9)
Smoking status, n (%)
Current 88 (14.2) 35 (35.4) 368 (47.3)
Former 87 (14.0) 37 (37.4) 268 (34.4)
Never 446 (71.8) 27 (27.3) 141 (18.1)
ACO asthma-COPD overlap, ACT asthma control test,
AQLQ asthma quality of life questionnaire, CAT COPD
assessment test, COPD chronic obstructive pulmonary disease,
FEV1 forced expiratory volume in 1 s, mMRC modiﬁed
Medical Research Council, n/a not applicable, SD standard
deviation
a Patients with missing data were excluded from percentage
calculations
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observed in patients who switched to the
Bufomix Easyhaler from another inhaler.
Effect of Bufomix Easyhaler on Health-
related Quality of Life
Patients with asthma had a mean (SD) mini-
AQLQ score of 3.8 (0.9) at baseline, indicating a
moderate impairment of QoL from asthma. A
significant improvement in mini-AQLQ score,
indicating some impairment, was observed by
visit 3 [5.2 (0.7); p\0.001] (Table 3).
Patients with COPD had a mean (SD) mMRC
score of 1.9 (0.9) at baseline, indicating that
most patients walk more slowly than people of
the same age because of breathlessness or must
stop for breath when walking at their own pace.
A significant improvement in the mMRC score
was observed by visit 3 [1.2 (0.8); p\0.001]
(Table 4).
Patient Satisfaction with the Use
of Bufomix Easyhaler and Physicians’
Assessments
Patients were asked to describe their percep-
tions of different attributes of their current
treatment from the multiple-choice questions
(Table 1). Overall, patient satisfaction was
higher for the Bufomix Easyhaler than for the
other inhalers (Fig. 3). Furthermore, more than
90.0% of physicians described the Bufomix
Easyhaler as easy to teach, with 98.9% of their
patients having learned the technique within
10 min and 73.8% within 5 min of teaching
(Fig. 4).
DISCUSSION
We present the first real-world PRO data col-
lected from patients with obstructive airway
disease using the Bufomix Easyhaler in
Table 3 Assessment of ﬁxed-dose budesonide/formoterol fumarate combination therapy on changes in PRO measures and
FEV1 (% predicted) in patients with asthma or ACO (n = 720)
Asthma (n = 621) ACO (n = 99)
Visit 1 Visit 3 p value Visit 1 Visit 3 p value
Asthma control test
All patients 14.2 (4.1) 21.0 (2.7) \ 0.001 13.6 (4.1) 18.7 (3.1) \ 0.001
Inhaler-naı¨ve patients 14.3 (4.0) 21.1 (2.6) \ 0.001 14.6 (3.0) 18.9 (1.9) 0.001
Patients switching to Easyhaler 14.2 (4.2) 20.9 (2.7) \ 0.001 13.4 (4.3) 18.7 (3.3) \ 0.001
Mini-AQLQ
All patients 3.8 (0.9) 5.2 (0.7) \ 0.001 3.7 (0.9) 4.6 (0.8) \ 0.001
Inhaler-naı¨ve patients 3.9 (0.9) 5.3 (0.7) \ 0.001 4.0 (0.8) 4.7 (0.7) \ 0.001
Patients switching to Easyhaler 3.8 (0.9) 5.1 (0.8) \ 0.001 3.6 (0.9) 4.6 (0.8) \ 0.001
FEV1 (% predicted)
All patients 76.7 (19.3) 85.3 (20.3) \ 0.001 56.7 (18.3) 62.4 (20.2) \ 0.001
Inhaler-naı¨ve patients 77.1 (19.6) 85.8 (19.7) \ 0.001 54.4 (17.3) 64.1 (17.1) \ 0.001
Patients switching to Easyhaler 76.4 (19.1) 85.0 (20.6) \ 0.001 57.2 (18.5) 62.0 (20.8) \ 0.001
Data are presented as mean (SD). p values refer to Wilcoxon’s signed rank test of change from baseline (visit 1) at visit 3
(week 12 of treatment)
ACO asthma-COPD overlap, AQLQ asthma quality of life questionnaire, PRO patient-reported outcome
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everyday practice in Hungary. The results
obtained demonstrate that most patients with
obstructive airway disease, treated with budes-
onide/formoterol fumarate combination ther-
apy (Bufomix Easyhaler), may obtain well-
controlled disease or complete control (ACT
score 20–25; CAT score\20) when treated in a
real-world study setting. Roughly 3 months
after switching to the Bufomix Easyhaler,
patients had improved lung function, and all
groups (including patients who switched from
another device to the Bufomix Easyhaler)
showed significant improvement in the quality
of life in all parameters assessed. No adverse
events were reported by the participating
physicians, supporting the safety profile of
Bufomix Easyhaler formulations for patients
with obstructive airway disease.
Overall, patients considered the Bufomix
Easyhaler as portable, easy to use and easy to
keep clean during daily activities. This
statement is supported by the continued use of
the Bufomix Easyhaler throughout the study,
with no discontinuations reported. Further-
more, study physicians reported that use of the
Bufomix Easyhaler was easy to teach, with
their patients learning inhaler use quickly. Our
data support previous patient preference data
(based on studies in children and adults) that
demonstrated the Easyhaler was easy to teach,
learn and use, coupled with more user satisfac-
tion [18, 32]; findings were recently confirmed
by a meta-analysis [19].
The Bufomix Easyhaler achieved well-con-
trolled disease or complete disease control
despite a high proportion of patients being
smokers. Patients were satisfied with the ther-
apy, and the Easyhaler was easy for them to
use. Most of our patient population had primary
or high school education; therefore, it is likely
that ease of use and adequate training on how
to use the inhaler were important in ensuring
Table 4 Assessment of ﬁxed-dose budesonide/formoterol fumarate combination therapy on changes in PRO measures and
FEV1 (% predicted) in patients with COPD or ACO (n = 877)
COPD (n = 778) ACO (n = 99)
Visit 1 Visit 3 p value Visit 1 Visit 3 p value
COPD assessment test
All patients 24.2 (5.7) 18.2 (5.1) \ 0.001 23.7 (6.5) 18.3 (4.7) \ 0.001
Inhaler-naı¨ve patients 23.8 (5.6) 17.9 (4.9) \ 0.001 23.1 (6.0) 18.7 (5.0) \ 0.001
Patients switching to Easyhaler 24.4 (5.8) 18.3 (5.1) \ 0.001 23.8 (6.6) 18.3 (4.6) \ 0.001
mMRC dyspnea scale
All patients 1.9 (0.9) 1.2 (0.8) \ 0.001 1.8 (0.9) 1.1 (0.9) \ 0.001
Inhaler-naı¨ve patients 1.7 (0.8) 1.0 (0.7) \ 0.001 1.5 (0.9) 0.8 (0.8) 0.002
Patients switching to Easyhaler 2.0 (0.9) 1.2 (0.8) \ 0.001 1.9 (0.9) 1.1 (0.9) \ 0.001
FEV1 (% predicted)
All patients 51.3 (17.0) 58.6 (17.9) \ 0.001 56.7 (18.3) 62.4 (20.2) \ 0.001
Inhaler-naı¨ve patients 54.9 (18.0) 63.8 (19.5) \ 0.001 54.4 (17.3) 64.1 (17.1) \ 0.001
Patients switching to Easyhaler 49.9 (16.4) 56.6 (16.9) \ 0.001 57.2 (18.5) 62.0 (20.8) \ 0.001
Data are presented as mean (SD). p values refer to Wilcoxon’s signed rank test of change from baseline (visit 1) at visit 3
(week 12 of treatment)
ACO asthma-COPD overlap, COPD chronic obstructive pulmonary disease, mMRC modiﬁed medical research council,
PRO patient-reported outcome
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the optimal dosing, as a suboptimal inhalation
technique may have clinical implications [14].
Our study provides real-world data using a
large representative sample of Hungarian
patients using the Bufomix Easyhaler in
everyday clinical practice. Although the analy-
ses were robust and performed using verified
questionnaires, the study has limitations. The
study was an open-label, non-parallel design
study with no comparator devices, and the
Fig. 1 Evaluation of disease control in a. Patients with
asthma or ACO (n = 720) and b. Patients with COPD or
ACO (n = 876) following 12 weeks’ treatment with
Bufomix Easyhaler. a Patients with asthma or ACO
(n = 720). b Patients with COPD or ACO (n = 876).
ACO asthma-COPD overlap, ACT asthma control test,
CAT COPD assessment test, COPD chronic obstructive
pulmonary disease
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study population may have biased the assess-
ment of patient preferences for inhaler device,
as only patients who were uncontrolled and
therefore likely to have been unsatisfied with
their previous inhaler were evaluated. Further-
more, data on patient adherence and product-
specific training for previous inhalers were
unavailable for inclusion. Conclusions on the
effectiveness of the Bufomix Easyhaler are also
limited by the lack of exacerbation data for
patients with asthma and COPD and direct
comparisons between inhalers.
There is a limited body of real-world data for
patient-reported outcomes with the Bufomix
Easyhaler. A similar trial to the current study
(though conducted in patients with asthma
Fig. 3 Patient satisfaction by inhaler type (visit 3, following 12 weeks’ treatment with the Bufomix Easyhaler; visit 1 for
other devices) (n = 1043). MDI metered dose inhaler
Fig. 2 Frequency of reliever inhaler use in patients with asthma (n = 619) or ACO (n = 99) following 12 weeks’ treatment
with the Bufomix Easyhaler. ACO asthma-COPD overlap
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only) was recently completed in Sweden; this
will report non-inferiority of asthma control [as
measured by ACT (primary end point)] in
patients who switched from the Symbicort
Turbuhaler (Astrazeneca, Cambridge, UK) to
Bufomix Easyhaler [33]. Future studies should
also evaluate whether improved effectiveness
and QoL outcomes with the Bufomix
Easyhaler versus comparators also translate
into improved long-term adherence.
CONCLUSION
The results obtained demonstrate the clinical
effectiveness of the Bufomix Easyhaler in the
treatment of outpatients with obstructive
Fig. 4 Physician assessment of a. Ease of use* and b. Time
taken to teach Easyhaler use** (asthma: n = 617; COPD:
n = 775; ACO: n = 98). *Evaluated at visits 1–3 (through
12 weeks’ treatment with the Bufomix Easyhaler);
**evalauted at visit 1, after initial teaching of Easyhaler
use to the patient by the physician. ACO asthma-COPD
overlap
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airway disease in routine daily clinical practice.
These data need to be verified in other popula-
tions where the Bufomix Easyhaler is approved
for use. Patients with uncontrolled airway
obstruction may benefit from switching their
inhaler therapy to the Bufomix Easyhaler.
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